These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37142929)

  • 81. Cell-Based No-Wash Fluorescence Assays for Compound Screens Using a Fluorescence Cytometry Plate Reader.
    Gorshkov K; Pradhan M; Xu M; Yang S; Lee EM; Chen CZ; Shen M; Zheng W
    J Pharmacol Exp Ther; 2020 Sep; 374(3):500-511. PubMed ID: 32532853
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Development of an in vitro drug sensitivity assay for Trichuris muris first-stage larvae.
    Wimmersberger D; Tritten L; Keiser J
    Parasit Vectors; 2013 Feb; 6():42. PubMed ID: 23433224
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The why and how of phenotypic small-molecule screens.
    Eggert US
    Nat Chem Biol; 2013 Apr; 9(4):206-9. PubMed ID: 23508174
    [No Abstract]   [Full Text] [Related]  

  • 84. A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells.
    Mathews LA; Keller JM; Goodwin BL; Guha R; Shinn P; Mull R; Thomas CJ; de Kluyver RL; Sayers TJ; Ferrer M
    J Biomol Screen; 2012 Oct; 17(9):1231-42. PubMed ID: 22927676
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Screening methods for ion-channels drug discovery and new ideas].
    Fujii M; Ohya S; Yamamura H; Imaizumi Y
    Nihon Yakurigaku Zasshi; 2011 Dec; 138(6):229-33. PubMed ID: 22156258
    [No Abstract]   [Full Text] [Related]  

  • 86. Using Functional Genetics in Haploid Cells for Drug Target Identification.
    Volz JC; Schuller N; Elling U
    Methods Mol Biol; 2019; 1953():3-21. PubMed ID: 30912012
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A High-Throughput Image Cytometry Method for the Formation, Morphometric, and Viability Analysis of Drug-Treated Mammospheres.
    Kessel SL; Chan LL
    SLAS Discov; 2020 Aug; 25(7):723-733. PubMed ID: 32396489
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs).
    Callis R; Rabow A; Tonge M; Bradbury R; Challinor M; Roberts K; Jones K; Walker G
    J Biomol Screen; 2015 Jul; 20(6):748-59. PubMed ID: 25851036
    [TBL] [Abstract][Full Text] [Related]  

  • 89. High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.
    Johnston PA; Sen M; Hua Y; Camarco D; Shun TY; Lazo JS; Grandis JR
    Assay Drug Dev Technol; 2014; 12(1):55-79. PubMed ID: 24127660
    [TBL] [Abstract][Full Text] [Related]  

  • 90. 96-well plate assay for sublethal metabolic activity.
    Yang Y; Balcarcel RR
    Assay Drug Dev Technol; 2004 Aug; 2(4):353-61. PubMed ID: 15357916
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A Protocol for a High-Throughput Multiplex Cell Viability Assay.
    Gilbert DF; Boutros M
    Methods Mol Biol; 2016; 1470():75-84. PubMed ID: 27581285
    [TBL] [Abstract][Full Text] [Related]  

  • 92. High-Throughput Screening to Identify Small Molecules That Selectively Inhibit APOL1 Protein Level in Podocytes.
    Choy J; Kan Y; Cifelli S; Johnson J; Chen M; Shiao LL; Zhou H; Previs S; Lei Y; Johnstone R; Liaw A; Saigal A; Hu L; Ramos R; Visconti R; McElroy WT; Kreamer A; Wildey MJ; Peier A; Shin MK; Imbriglio J; Ren Z; Hoek M; Weinglass A; Ai X
    SLAS Discov; 2021 Oct; 26(9):1225-1237. PubMed ID: 34218698
    [TBL] [Abstract][Full Text] [Related]  

  • 93. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system.
    Lee N; Shum D; König A; Kim H; Heo J; Min S; Lee J; Ko Y; Choi I; Lee H; Radu C; Hoenen T; Min JY; Windisch MP
    Antiviral Res; 2018 Oct; 158():226-237. PubMed ID: 30149038
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Concise review: drug discovery in the age of the induced pluripotent stem cell.
    Ko HC; Gelb BD
    Stem Cells Transl Med; 2014 Apr; 3(4):500-9. PubMed ID: 24493856
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The application of phenotypic high-throughput screening techniques to cardiovascular research.
    Etzion Y; Muslin AJ
    Trends Cardiovasc Med; 2009 Aug; 19(6):207-12. PubMed ID: 20211437
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection.
    Balani SK; Miwa GT; Gan LS; Wu JT; Lee FW
    Curr Top Med Chem; 2005; 5(11):1033-8. PubMed ID: 16181128
    [TBL] [Abstract][Full Text] [Related]  

  • 97. An image-based assay to quantify changes in proliferation and viability upon drug treatment in 3D microenvironments.
    Murali VS; Chang BJ; Fiolka R; Danuser G; Cobanoglu MC; Welf ES
    BMC Cancer; 2019 May; 19(1):502. PubMed ID: 31138163
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Use of the hollow fiber assay for the evaluation of DNA damaging agents.
    Veiga JP; Cooper PA; Pors K; Patterson LH; Bibby MC; Shnyder SD
    J Pharmacol Toxicol Methods; 2011; 64(3):226-32. PubMed ID: 21569858
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Protocol development for discovery of angiogenesis inhibitors via automated methods using zebrafish.
    Mauro A; Ng R; Li JY; Guan R; Wang Y; Singh KK; Wen XY
    PLoS One; 2019; 14(11):e0221796. PubMed ID: 31730619
    [TBL] [Abstract][Full Text] [Related]  

  • 100. An optimized lactate dehydrogenase release assay for screening of drug candidates in neuroscience.
    Kaja S; Payne AJ; Singh T; Ghuman JK; Sieck EG; Koulen P
    J Pharmacol Toxicol Methods; 2015; 73():1-6. PubMed ID: 25681780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.